Drug intelligence / Profile preview

GW912

Development stage: Preclinical
Lead developer: TechGowell
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GW912 is a small interfering RNA (siRNA) therapeutic candidate being developed by TechGowell for the treatment of chronic respiratory diseases, specifically asthma and chronic obstructive pulmonary disease (COPD). The drug utilizes RNA interference (RNAi) technology to silence the expression of a specific gene involved in the inflammatory or pathological processes of these airway conditions. As of the current development cycle, GW912 is in the preclinical stage, and its specific molecular target has not been publicly disclosed by the developer.

Beyond the preview

Go deeper on GW912.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW912.

Explore the full profile